NeuroBo Pharmaceuticals, Inc.

The momentum for this stock is not very good. NeuroBo Pharmaceuticals, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in NeuroBo Pharmaceuticals, Inc..
Log in to see more information.
NRBO Fundamental Data by TradingView

News

NeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Down 4.9%
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Shares Down 4.9%

Ticker Report NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO - Get Free Report)'s share price fell 4.9% during trading on Tuesday . The company traded as low as $3.50 and last traded at $3.51. 22,860 shares traded...\n more…

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire CAMBRIDGE...\n more…

NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024
NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nNRBO stock results show that NeuroBo Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.\nThe...\n more…

NeuroBo Pharmaceuticals reports Q2 EPS ($1.85), consensus ($1.12)
NeuroBo Pharmaceuticals reports Q2 EPS ($1.85), consensus ($1.12)

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update...\n more…

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

PR Newswire NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity NeuroBo...\n more…